Astellas’ ASP1128 Receives the US FDA’s Fast Track Designation for Patients at High Risk of Acute Kidney Injury

 Astellas’ ASP1128 Receives the US FDA’s Fast Track Designation for Patients at High Risk of Acute Kidney Injury

Astellas’ ASP1128 Receives the US FDA’s Fast Track Designation for Patients at High Risk of Acute Kidney Injury

Shots:

  • The US FDA has granted FT designation to the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury (AKI) after coronary artery bypass and/or valve (CABG/V) surgery
  • In 2018, Astellas acquired Mitobridge to focus on developing mitochondrial-directed therapies and recognizes the serious burden of AKI on patients. The development of its lead candidate, ASP1128 will robust Astellas’ mitochondrial dysfunction pipeline
  • ASP1128 is a selective modulator of PPARδ intended to have protective effects on kidney cells that under cellular stress following CABG/V surgery by promoting fatty acid oxidation in the mitochondria

Click here to­ read full press release/ article | Ref: Astellas | Image: STAT

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post